Sanofi to acquire Vicebio, expanding respiratory vaccines pipeline
Sanofi announces it has entered into an agreement to acquire Vicebio Ltd, a privately held biotechnology company headquartered in London, UK. The acquisition brings an early-stage combination vaccine candidate for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), both respiratory viruses, and expands…
